Hypolipaemic activity of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate) and its analogues in normolipaemic rats.
The hypolipaemic potential of 1-(theophyllin-7-yl)-ethyl-2-[2-(p-chlorophenoxy)-2-methylpropionate] (etofylline clofibrate, ML 1024, Duolip) was assessed in conjunction with a series of analogous new theophylline derivatives and clofibrate (CPIB) by a short-term screening test in normolipaemic rats. The significant cholesterol and triglyceride-lowering effect of ML 1024 was comparable to that observed for CPIB over the 50-300 mg/kg dose range evaluated and contrasted with the relative inactivity associated with its chemical analogues.
D000818:Animals; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000031:analogs & derivatives* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D000960:Hypolipidemic Agents; D008055:Lipids / Q000097:blood; D008297:Male; D051381:Rats; D014280:Triglycerides / Q000097:blood
D000960:Hypolipidemic Agents; D008055:Lipids; D014280:Triglycerides; C028764:etofylline clofibrate; D002784:Cholesterol; D002994:Clofibrate